Design Therapeutics Inc (DSGN)
3.38
+0.07
(+2.11%)
USD |
NASDAQ |
Jun 21, 16:00
3.36
-0.02
(-0.59%)
After-Hours: 20:00
Design Therapeutics Research and Development Expense (Quarterly): 9.801M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 9.801M |
| December 31, 2023 | 11.01M |
| September 30, 2023 | 13.26M |
| June 30, 2023 | 17.06M |
| March 31, 2023 | 15.73M |
| December 31, 2022 | 14.26M |
| September 30, 2022 | 14.30M |
| June 30, 2022 | 11.30M |
| March 31, 2022 | 8.759M |
| Date | Value |
|---|---|
| December 31, 2021 | 7.337M |
| September 30, 2021 | 8.539M |
| June 30, 2021 | 5.027M |
| March 31, 2021 | 3.875M |
| December 31, 2020 | 2.708M |
| September 30, 2020 | 1.914M |
| June 30, 2020 | 1.061M |
| March 31, 2020 | 0.377M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.377M
Minimum
Mar 2020
17.06M
Maximum
Jun 2023
8.607M
Average
8.759M
Median
Mar 2022
Research and Development Expense (Quarterly) Benchmarks
| Biogen Inc | 452.90M |
| AbbVie Inc | 1.939B |
| PTC Therapeutics Inc | 116.13M |
| Revance Therapeutics Inc | 14.39M |
| Context Therapeutics Inc | 1.973M |